jobs.jnj.com/en/jobs/

Skip to content

✕

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.

Home Link (JNJ Logo)

Home Link (JNJ Logo)

Home Link (JNJ Logo)

Home Link (JNJ Logo)

Our Stories

Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage

Our Company

Our COVID-19 Efforts
- The Road to a Vaccine
About J&J
Products
Suppliers
Careers
Media Center
Investors
Our Societal Impact

Quick Links

Latest News
Careers
Privacy Policy
About J&J
Media Center
Cookie Policy
Legal Notice
Products
Investors
Employees
Suppliers
Our Societal Impact
Contact Us
Credo Integrity Line

More From Johnson & Johnson

Janssen

Janssen

Pharmaceutical Companies of Johnson & Johnson
Johnson & Johnson MedTech

Johnson & Johnson MedTech

Reimagining the Way Healthcare Is Delivered
Johnson & Johnson Consumer Health

Johnson & Johnson Consumer Health

Meeting the Personal Care and Wellness Needs of Consumers Worldwide
Our Consumer Safety and Care Commitment

Our Consumer Safety and Care Commitment

Your Safety Is Our Priority
Johnson & Johnson Innovation

Johnson & Johnson Innovation

Advancing New Healthcare Solutions Through Collaboration
Johnson & Johnson Our Story

Johnson & Johnson Our Story

Learn About the Company's Rich Heritage at Our Digital Museum

Follow Us

Facebookfacebook
Instagraminstagram
LinkedInlinkedin
Twittertwitter
YouTubeyoutube

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.

Do Not Sell or Share My Personal Information
Limit the Use of My Sensitive Personal Information

All contents © Copyright Johnson & Johnson Services, Inc. 1997-2023. All Rights Reserved.

Explore more Johnson & Johnson sites:

Australia

Argentina

Brazil

Canada

Consumer Health

Janssen

MedTech

Chile

China

Colombia

Costa Rica

Czech Republic

Ecuador

France

Germany

India

Japan

Mexico

New Zealand / Pacific

Paraguay

Peru

Philippines

Russia

Switzerland

German

English

French

United Kingdom

United States

Uruguay

Venezuela

Search input

Share

Latest COVID-19 News

Latest News

March 08, 2022

Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa
Innovation

January 06, 2022

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States
Innovation

December 30, 2021

Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Innovation

December 15, 2021

Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
Innovation

December 09, 2021

World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
Innovation

December 05, 2021

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
Innovation

November 24, 2021

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older
Our Company

November 10, 2021

Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World’s Most Vulnerable People through Novel Humanitarian Buffer
October 21, 2021

U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
October 20, 2021

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Media Statement

October 18, 2021

17 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to African Union Countries
Innovation

October 15, 2021

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Innovation

October 05, 2021

Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
Our Company

September 28, 2021

Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes
Innovation

September 21, 2021

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Our Company

August 25, 2021

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
Media Statement

July 28, 2021

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine
Media Statement

July 14, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
Our Company

July 09, 2021

Johnson & Johnson Statement on U.S. Government Donations of Company’s COVID-19 Vaccine
Our Company

July 01, 2021

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Our Company

April 23, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
Our Company

April 20, 2021

Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review

EMA Confirms Overall Benefit-Risk Profile Remains Positive
Our Company

April 02, 2021

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
Our Company

March 29, 2021

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate
Our Company

March 12, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Our Company

March 11, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
Our Company

March 11, 2021

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
Our Company

March 05, 2021

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
Our Company

February 28, 2021

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
October 20, 2021

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Our Company

February 26, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
Our Company

February 19, 2021

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Our Company

February 16, 2021

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Innovation

February 04, 2021

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Our Company

January 29, 2021

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Our Company

January 13, 2021

Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
Our Company

December 18, 2020

Johnson & Johnson Announces Agreement in Principle with Gavi to Supply Janssen’s COVID-19 Vaccine Candidate
to Lower-Income Countries in 2021
Our Company

December 17, 2020

Johnson & Johnson Announces Its First Phase 3 COVID-19 Vaccine Trial ENSEMBLE is Fully Enrolled
Our Company

December 01, 2020

Johnson & Johnson Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada
Our Company

October 23, 2020

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Latest News

September 30, 2020

Life Science Companies and the Bill & Melinda Gates Foundation: Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines
Our Company

September 25, 2020

(This statement was updated on October 4, 2020 to include additional information)

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate
Our Company

September 23, 2020

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Our Company

September 08, 2020

Biopharma Leaders Unite To Stand With Science
Our Company

September 03, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Our Company

August 31, 2020

Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate
Our Company

August 14, 2020

Johnson & Johnson Announces Collaboration in Principle with the United Kingdom on Additional Phase 3 Study and Agreement to Supply its COVID-19 Vaccine Candidate
Our Company

August 05, 2020

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Our Company

July 30, 2020

Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Our Company

June 10, 2020

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Our Company

April 23, 2020

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company’s Goal to Supply More Than One Billion Vaccine Doses Globally
Innovation

April 23, 2020

Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics
Our Company

March 30, 2020

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Our Company

March 16, 2020

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Our Company

March 13, 2020

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development
Innovation

February 18, 2020

Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
Our Company

January 29, 2020

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat

Quick Links

Latest News
Careers
Privacy Policy
About J&J
Media Center
Cookie Policy
Legal Notice
Products
Investors
Employees
Suppliers
Our Societal Impact
Contact Us
Credo Integrity Line

More From Johnson & Johnson

Janssen

Janssen

Pharmaceutical Companies of Johnson & Johnson
Johnson & Johnson MedTech

Johnson & Johnson MedTech

Reimagining the Way Healthcare Is Delivered
Johnson & Johnson Consumer Health

Johnson & Johnson Consumer Health

Meeting the Personal Care and Wellness Needs of Consumers Worldwide
Our Consumer Safety and Care Commitment

Our Consumer Safety and Care Commitment

Your Safety Is Our Priority
Johnson & Johnson Innovation

Johnson & Johnson Innovation

Advancing New Healthcare Solutions Through Collaboration
Johnson & Johnson Our Story

Johnson & Johnson Our Story

Learn About the Company's Rich Heritage at Our Digital Museum

Follow Us

Facebookfacebook
Instagraminstagram
LinkedInlinkedin
Twittertwitter
YouTubeyoutube

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.

Do Not Sell or Share My Personal Information
Limit the Use of My Sensitive Personal Information

All contents © Copyright Johnson & Johnson Services, Inc. 1997-2023. All Rights Reserved.

Back to top

You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.